Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > $6 is going to be a new wall for a few months

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Feb 24, 2021 12:59pm

157 Views

Post# 32647961

RE:$6 is going to be a new wall for a few months

I agree Act - $6 is the new $4. But, if the amalgamation NR clearly stipulates the transfer of patents, this could be a spark to push the SP north. I look to Dan and Stern (are they still on retainer?) to really maximize that benefit, and communicate it effectively. It's an ask you'd think would a no-brainer, but, I'm not sure they'll communicate like that.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?